Clinical trial for PLB1004

Clinical trials are currently under way for PLB1004 on non-small cell lung cancer with respect to treatment of EGFR/HER2 Exon 20 insertion mutation. Data reveal that the drug shows effective treatment and safety and will benefit 60%+ of lung cancer patients. Clinical trials are also currently ongoing for PLB1004 on non-small cell lung cancer with respect to treatment of EGFR sensitive mutation (19 Exon deletion mutation and 21 Exon L858R mutation).

PLB1004 worldwide multi-center clinical trials will soon be carried out in the U.S.